explore -WSS

explore

author：hotspot 2025-09-30 22:27:44 - browse：16

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Covid misinformation case heads to Supreme Court

leisure time

entertainment

WSS

Carvykti CAR

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

General Catalyst, Summa Health deal will turn on physician buy

The real point of Kenneth Smith’s execution by nitrogen gas

Some dementia cases could be undiagnosed liver disease

What we need to know about Arena Bioworks

entertainment

explore

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Can sheer will power keep patients alive in their dying hours?

How one medical school became remarkably diverse

Carvykti CAR

Sports medicine is finally prioritizing gender equality

Medicare drug price negotiation’s day in court

Affirmative action in medical school literally saved lives

In Spain, a hospital brews its own CAR

Apple is now the first public company to be valued at $3 trillion

Can sheer will power keep patients alive in their dying hours?

hotspot

Medicare drug price negotiation’s day in court

How to keep neuroscience’s past racism from being its future

Medicare Advantage beneficiaries sue Humana over algorithm use

Covid misinformation case heads to Supreme Court

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

leisure time

entertainment

entertainment

entertainment